Citations

Clear

16280 citation(s) found for "Yu, David".

The Impact of Melphalan Conditioning and CD34+ Cell Dose and Schedule on Post‐Transplant Outcomes in AL Amyloidosis
Muchtar, Eli , Sanchorawala, Vaishali , Hassan, Hamza , Hegenbart, Ute , Lee, Hans C. , Qazilbash, Muzaffar H. , Kin, Andrew , Zonder, Jeffrey A. , Jacob, Eapen, Dingli, David , Arai, Sally , Chin, Michelle M. , Lentzsch, Suzanne , Magen, Hila , Shkury, Eden , Sarubbi, Caitlin, Landau, Heather , Lee, Hans C , Qazilbash, Muzaffar H , Dispenzieri, Angela , Chakraborty, Rajshekhar , Magen, Hila , Gertz, Morie A , Muchtar, E , Dingli, David , Hegenbart, Ute , Sanchorawala, Vaishali , Hassan, Hamza , Schönland, Stefan , Buadi, Francis K. , Dispenzieri, Angela , Chakraborty, Rajshekhar , Gertz, Morie A.

Mayo Clinic

American Journal of Hematology | April 11, 2025 | Volume: 100 | Issue: 7 | Pages: 1141-1151

10.1002/ajh.27685 | PMID 40214172 Get It

ABSTRACTThe optimal conditioning schedule and CD34+ cell dose for autologous stem cell transplantation (ASCT) for AL amyloidosis is unknown. Patients (n = 1704) who underwent ASCT for AL amyloidosis between 2003 and 2020 in 9 centers were included. Data on melphalan conditioning dose, number of conditioning days, whether a rest day between conditioning and stem cell infusion was given or not, and infused CD34+ cell dose were collected. Full‐dose melphalan (≥ 180 mg/m2) was administered in 63.7% of the patients, and 80.4% had melphalan split into 2‐day conditioning. A rest day (day −1) between the conditioning regimen and stem cell infusion was provided in 52.5% of patients. The median infused CD34+ cell count was 4.7 × 106/kg. An infused CD34+ cell count ≥ 4.5 × 106/kg was associated with a shorter time to neutrophil and platelet engraftment. In a nominal regression analysis, full‐dose melphalan, 1‐day melphalan conditioning, and omitting a rest day between conditioning and stem cell infusion were independent predictors of post‐ASCT higher deep hematological response. The median follow‐up was 8.6 years, and 38% of patients died. Independent predictors of superior overall survival in multivariate Cox regression analysis included full‐dose melphalan, having no rest day, and infused CD34+ cells ≥ 4.5 × 106/kg. Independent predictors of higher day‐100 transplant‐related mortality (TRM) in nominal logistic regression analysis included poorer performance status, NT‐proBNP/BNP ≥ 1800/400 pg/mL, serum albumin < 2.5 g/dL, CD34+ cells < 4.5 × 106/kg, and not having a rest day. In conclusion, 1 day of melphalan conditioning and administration of CD34+ cells ≥ 4.5 × 106/kg are recommended for ASCT in AL amyloidosis.
Pregnancy and Parity as Risk Factors for Recurrence in Idiopathic Subglottic Stenosis
Awadallah, Andrew S. , Fearington, Forrest W. , Khalil, Yousuf H. , Ali, Hawa M. , Li, Yan , Francis, David O. , Dailey, Seth H. , Edell, Eric S. , Ekbom, Dale C. , Bayan, Semirra L. , Awadallah, Andrew , Bowen, Andrew J. , Koster, Matthew J.

Mayo Clinic

Otolaryngology–Head and Neck Surgery | April 11, 2025 | Volume: 173 | Issue: 2 | Pages: 447-452

10.1002/ohn.1255 | PMID 40211691 Get It

AbstractObjectiveThis study aims to evaluate the impact of parity on the severity and recurrence rates of idiopathic subglottic stenosis (iSGS) in premenopausal females.Study DesignA retrospective cohort study.SettingTwo tertiary care centers from 2002 to 2024.MethodsWe analyzed premenopausal iSGS patients under 40 years who underwent balloon dilation or laser wedge excision. Clinical features, including demographics and pregnancy history, were examined. Recurrence rates between nulliparous and parous patients were compared using Poisson regression, adjusting for age and follow‐up duration. Linear regression assessed the relationship between pregnancy and iSGS recurrence.ResultsForty‐eight patients were included, with 36 parous and 12 nulliparous. Adjusting for age and follow‐up, the mean recurrence rate was 2.6 times higher in parous patients (95% confidence interval [CI]: [1.5, 4.8], P = .0008). Each additional pregnancy was associated with 0.81 additional recurrences (95% CI: [0.05, 1.57], P = .0375). No significant differences in surgery‐free time were observed between groups.ConclusionParity and pregnancy significantly increase the risk of iSGS recurrence, although they do not accelerate subsequent recurrences. Health care providers should counsel women of childbearing age about these risks in family planning discussions, emphasizing shared decision‐making regarding potential surgical interventions.Level of evidence3.
Value of Artificial Intelligence for Enhancing Suspicion of Cardiac Amyloidosis Using Electrocardiography and Echocardiography: A Narrative Review
Grogan, Martha , López-Jiménez, Francisco , Guthrie, Spencer , Kumar, Nisith, Langevin, R.Eugene, Lousada, Isabelle , Witteles, Ronald , Royyuru, Ajay K. , Rosenzweig, Michael , Cairns‐Smith, Sarah , Royyuru, Ajay , Ouyang, David , Lopez-Jimenez, Francisco , Kumar, Nisith, Langevin, Reuben

Mayo Clinic

Journal of the American Heart Association | April 10, 2025 | Volume: 14 | Issue: 8 | Pages: No page available

10.1161/jaha.124.036533 | PMID 40207501 Get It

Nonspecific symptoms and other diagnostic challenges lead to underdiagnosis of cardiac amyloidosis (CA). Artificial intelligence (AI) could help address these challenges, but a summary of the performance of these tools is lacking. This narrative review of published literature describes the performance of AI tools that use data from ECGs and echocardiography to improve identification of CA and challenges that hinder adoption of these tools. Thirteen studies met inclusion criteria with sample sizes ranging from 50 to 2451 patients. Four studies used ECG data, 8 used echocardiography data, and 1 used both. The CA gold standard was typically defined as a CA diagnosis in an institutional or other database but the requirements for these diagnoses were heterogenous across studies, and many did not distinguish among CA subtypes. AI model development varied considerably, and only 4 studies included external validation. The ability of models to predict CA ranged from 0.71 to 1.00, sensitivity ranged from 16% to 100%, and specificity from 75% to 100%. Only 1 study reported model performance across strata of sex, age, race, and CA type. Persistent challenges to AI adoption include usability, cost, value added, electronic health record/information technology interoperability, patient‐related factors, regulation, and privacy and liability. Published studies on AI for improved identification of CA show favorable performance measures but numerous methodologic and other challenges must be addressed before these tools are more widely adopted.
Clonal Hematopoiesis of Indeterminate Potential in Chronic Coronary Disease: A Report From the ISCHEMIA Trials Biorepository
Muller, Matthew , Liu, Richard , Shah, Farheen , Held, Claes , Kullo, Iftikhar J. , McManus, Bruce M. , Wallentin, Lars , Newby, L. Kristin , Sidhu, Mandeep S. , Muller, Matthew A , Hu, Jiyuan , Held, Claes , Kullo, Iftikhar J , Wallentin, Lars , Newby, L Kristin , Bangalore, Sripal , Reynolds, Harmony R , Hochman, Judith S , Maron, David J , Ruggles, Kelly V , Berger, Jeffrey S , Newman, Jonathan D , Bangalore, Sripal , Reynolds, Harmony R. , Hochman, Judith S. , Maron, David J. , Berger, Jeffrey S.

Mayo Clinic

Circulation: Genomic and Precision Medicine | April 10, 2025 | Volume: 18 | Issue: 3 | Pages: No page available

10.1161/circgen.124.004921 | PMID 40207358 Get It

NCCN Guidelines® Insights: Testicular Cancer, Version 2.2025
Lin, Daniel W. , Feldman, Darren R., Aggarwal, Rahul , Drakaki, Alexandra , Eggener, Scott E. , Humphrey, Peter A. , Leuva, Harshraj , Levine, Ellis G., Maughan, Benjamin L. , Reichert, Zachery R. , Rwigema, Jean‐Claude M. , Shah, Sumit, Singla, Nirmish, Sircar, Kanishka , Zhumkhawala, Ali , Sliker, Bailee , Gilligan, Timothy D. , Adra, Nabil , Bagrodia, Aditya , Yamoah, Kosj , Chandrasekar, Thenappan , Costa, Daniel Nobrega da , Drakaki, Alexandra , Emamekhoo, Hamid , Geynisman, Daniel M. , Graham, Laura , Luckenbaugh, Amy N. , McGregor, Bradley A. , Monk, Paul , Picus, Joel , Pierorazio, Phillip , Rais‐Bahrami, Soroush , Saylor, Philip J. , Shah, Ankeet , Shah, Sumit, VanderWeele, David James , Montgomery, Sarah E.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | April 9, 2025 | Volume: 23 | Issue: 4 | Pages: No page available

10.6004/jnccn.2025.0018 | PMID 40203876 Get It

The NCCN Guidelines for Testicular Cancer provide recommendations for the multidisciplinary approach to the diagnostic workup, treatment, and follow-up for testicular germ cell tumors, including both seminoma and nonseminoma. These NCCN Guidelines Insights discuss the current treatment recommendations and supporting clinical data for seminomas as presented in Version 2.2025 of the NCCN Guidelines for Testicular Cancer.
Antitumor Activity of Vebreltinib and Characterization of Clinicogenomic Features in Solid Tumors with MET Rearrangements
Nakazawa, Seshiru , Pecci, Federica , Odintsov, Igor , Gazgalis, Dimitris , Gottlieb, Felix H. , Ricciuti, Biagio , Zullo, Lodovica , Alessi, Joao V. , Federico, Alessandro Di , Aldea, Mihaela , Garbo, Edoardo , Saini, Arushi , Jiang, Jie , Baldacci, Simon , Makarem, Maisam , Locquet, Marie-Anaïs , Haradon, Danielle , Italiano, Antoîne , Lavaud, Pernelle , Vasseur, Damien , Planchard, David , Watanabe, Y., Mahran, Hoda A., Niu, Jiaxin , Swan, Leong Swan, Tay, Kevin , Kizilbash, Sani H. , Yu, Kin-Hung P. , Zhang, Xiaoling , Chen, Pan , Sangem, Mythili, Che, Jianwei , Sholl, Lynette M. , Jänne, Pasi A. , Di Federico, Alessandro , Gandhi, Malini M , Saini, Arushi , Feng, William W , Jiang, Jie , Baldacci, Simon , Facchinetti, Francesco , Makarem, Maisam , Locquet, Marie-Anaïs , Haratani, Koji , Haradon, Danielle , Besse, Benjamin , Italiano, Antoine , Remon, Jordi , Lavaud, Pernelle , Vasseur, Damien , Planchard, David , Sato, Yusuke , Watanabe, Yukako , Owen, Scott , Cortot, Alexis B , Mahran, Hoda , Forster, Martin D , Niu, Jiaxin , Tomasini, Pascale , Leong, Swan Swan , Tay, Kevin , Esteban, Emilio , Minchom, Anna , Kizilbash, Sani H , Cruz-Correa, Marcia , Yu, Kin-Hung Peony , Zhang, Xiaoling , Chen, Pan , Sangem, Mythili , Che, Jianwei , Sholl, Lynette , Jänne, Pasi A , Awad, Mark M , Odintsov, Igor , Ricciuti, Biagio , Aldea, Mihaela , Garbo, Edoardo , Gazgalis, Dimitris , Besse, Benjamin , Cortot, Alexis B. , Tomasini, Pascale , Cruz‐Correa, Marcia , Awad, Mark M.

Mayo Clinic

Cancer Discovery | April 9, 2025 | Volume: 15 | Issue: 6 | Pages: 1129-1140

10.1158/2159-8290.cd-24-1726 | PMID 40202082 Get It

Abstract Oncogenic translocations involving the MET gene have been reported in several cancer types, but detailed clinicogenomic characterization of these cancers is not well defined. In addition, prospective clinical trials evaluating the antitumor activity of MET inhibitors in MET rearrangement–positive cancers are limited. In this study, in a pan-cancer analysis of &gt;46,000 solid tumors with comprehensive genomic profiling, we identified oncogenic MET rearrangements in ∼0.04% of cancers. Preliminary analysis from a phase II clinical trial of the type I MET tyrosine kinase inhibitor (TKI) vebreltinib in MET fusion–positive solid tumors demonstrated an objective response rate of 50% and disease control rate of 79%, with antitumor activity seen in diverse cancer types, including lung adenocarcinoma and intrahepatic cholangiocarcinoma, among others. Similar to MET exon 14–altered lung cancer, secondary mutations in the kinase domain can confer resistance to MET TKIs in MET fusion–positive cancers. Overall, these data categorize MET rearrangements as actionable targets in solid tumors. Significance: MET rearrangement–positive cancers are not well-characterized, and optimal treatment strategies are yet to be defined. Through comprehensive genomic analysis, preclinical modeling, and preliminary results of a phase II clinical trial, we demonstrate that MET fusions are a unique molecular subtype of cancers targetable with vebreltinib, a TKI in development.
Letter to the FDA Proposing Major Changes in the US Clozapine Package Insert Supported by Clozapine Experts Worldwide. Part I
León, José de , Baldessarini, Ross J. , Balon, Richard , Bilbily, John , Citrome, Leslie , Cotes, Robert O. , Davis, John M. , DeLisi, Lynn E. , Faden, Justin , Freudenreich, Oliver , Goldsmith, David R. , Gurrera, Ronald J. , Josiassen, Richard C. , Kelly, Deanna L. , Laitman, Robert S., Lam, Y. W. Francis , Love, Raymond C. , McCollum, Betsy , Meyer, Jonathan M. , Nasrallah, Henry A. , Nucifora, Frederick C. , Rothschild, Anthony J. , Shelton, Charles , Sher, Leo , Zarzar, Theodore R. , Sanz, Emílio J. , Cuevas, Carlos De las , de Leon, Jose , Caroff, Stanley N , Citrome, Leslie , Correll, Christoph Ulrich , Cotes, Robert O , Davis, John M , Faden, Justin , Freudenreich, Oliver , Gurrera, Ronald , Kane, John M , Laitman, Robert S , Lam, Y W Francis , Leung, Jonathan G , Love, Raymond C , McCollum, Betsy , McGrane, Ian , Meyer, Jonathan M , Nasrallah, Henry A , Rothschild, Anthony J , Rubio, Jose M , Sarpal, Deepak K , Schoretsanitis, Georgios , Shad, Mujeeb , Shelton, Charles , Sher, Leo , Singh, Balwinder , Surya, Sandarsh , Zarzar, Theodore R , Sanz, Emilio J , De Las Cuevas, Carlos , Kane, John M. , Keshavan, Matcheri S. , Leung, Jonathan G. , McGrane, Ian R. , Sajatovic, Martha , Schoretsanitis, Georgios , Singh, Balwinder

Mayo Clinic

Journal of Clinical Psychopharmacology | April 8, 2025 | Volume: 45 | Issue: 3 | Pages: 179-196

10.1097/jcp.0000000000001987 | PMID 40198781 Get It

Abstract Purpose/Background Clozapine was approved in the United States (US) using 1989 regulations and knowledge. After 30 years, many sections of the US package insert (PI) are outdated. Methods We comprehensively reviewed the literature to propose PI updates. We present the information in 2 articles. In Part I, we focus on basic pharmacology based on 407 relevant articles. Part II focuses on clinical aspects and pharmacovigilance. Findings/Results Based on more recent expectations of Food and Drug Administration regulations, we reviewed clozapine basic pharmacology including the following: 1) clearance, 2) pharmacokinetics and pharmacodynamics, and 3) monitoring tools. We identified 9 major problems in the basic pharmacological sections of the PI including the following: 1) in vivo studies indicate that clozapine is dependent on CYP1A2 for its metabolism, 2) the minor role of CYP2D6 in clozapine metabolism requires removing the PI recommendation to lower clozapine doses in CYP2D6 poor metabolizers, 3) in nontoxic concentrations CYP3A4 has a minor role in clozapine metabolism and potent CYP3A4 inhibitors lack clinically relevant effects, 4) several drug-drug interactions need to be updated based on recent literature, 5) systemic inflammation may decrease clozapine metabolism and increase the risk of clozapine intoxication, 6) obesity may decrease clozapine metabolism, 7) patients of Asian and Indigenous American ancestry need lower clozapine doses, 8) personalized titration and c-reactive protein monitoring should be considered until prospective studies are available, and 9) the half-life section needs to be modified to acknowledge that single dosing at night is frequent in the US. Implications/Conclusions An improvement in the US clozapine PI may lead to improvement in PIs worldwide.
Letter to the FDA Proposing Major Changes in the US Clozapine Package Insert Supported by Clozapine Experts Worldwide. Part II
León, José de , Baldessarini, Ross J. , Balon, Richard , Bilbily, John , Citrome, Leslie , Cotes, Robert O. , Davis, John M. , DeLisi, Lynn E. , Faden, Justin , Freudenreich, Oliver , Goldsmith, David R. , Gurrera, Ronald J. , Josiassen, Richard C. , Kelly, Deanna L. , Laitman, Robert S., Lam, Y. W. Francis , Love, Raymond C. , McCollum, Betsy , Meyer, Jonathan M. , Nasrallah, Henry A. , Nucifora, Frederick C. , Rothschild, Anthony J. , Shelton, Charles , Sher, Leo , Zarzar, Theodore R. , Sanz, Emílio J. , Cuevas, Carlos De las , de Leon, Jose , Caroff, Stanley N , Citrome, Leslie , Correll, Christoph Ulrich , Cotes, Robert O , Davis, John M , Faden, Justin , Freudenreich, Oliver , Gurrera, Ronald , Kane, John M , Laitman, Robert S , Lam, Y W Francis , Leung, Jonathan G , Love, Raymond C , McCollum, Betsy , McGrane, Ian , Meyer, Jonathan M , Nasrallah, Henry A , Rothschild, Anthony J , Rubio, Jose M , Sarpal, Deepak K , Schoretsanitis, Georgios , Shad, Mujeeb , Shelton, Charles , Sher, Leo , Singh, Balwinder , Surya, Sandarsh , Zarzar, Theodore R , Sanz, Emilio J , De Las Cuevas, Carlos , Kane, John M. , Keshavan, Matcheri S. , Leung, Jonathan G. , McGrane, Ian R. , Sajatovic, Martha , Schoretsanitis, Georgios , Singh, Balwinder

Mayo Clinic

Journal of Clinical Psychopharmacology | April 8, 2025 | Volume: 45 | Issue: 3 | Pages: 197-218

10.1097/jcp.0000000000001990 | PMID 40198784 Get It

Abstract Purpose/Background This is the second part of a 2-part article that proposes improving the United States (US) clozapine package insert. Part II focuses on fatal outcomes and the 5 boxed warnings, 4 specifically for clozapine: severe neutropenia, seizure, orthostatic hypotension and myocarditis, and 1 for all antipsychotics (elderly with dementia). Methods US reports to the World Health Organization's global pharmacovigilance database were analyzed from clozapine's introduction to January 15, 2023. Findings/Results The US was the top reporter worldwide for clozapine with 56,003 reports and 9587 associated fatal outcomes. The 4 clozapine boxed warnings were associated with 534 fatal outcomes (218 with severe neutropenia, 131 with seizures, 125 with orthostasis, 36 with myocarditis, 24 with cardiomyopathy, and 0 with mitral valve prolapse). With no boxed warnings, pneumonia was associated with 674 fatal outcomes and increased white blood cell count (a sign of infection) with 596 fatal outcomes. After considering overlaps, pneumonia and increases in white blood cell count explained 900 fatalities, or 9.4% of 9587 fatal outcomes. The Food and Drug Administration continues to focus on severe neutropenia which was associated with only 218 or 2.3% of fatal outcomes, whereas 97.7% of fatal outcomes reported in US clozapine-treated patients had another cause. Implications/Conclusions To help prevent future deaths in clozapine-treated patients, the clozapine package insert should focus on fatal outcomes during infections. Part II offers detailed solutions regarding current boxed warnings and lack of a warning for pneumonia and other infections. The Supplementary Material includes letters of support from 124 non-US clozapine experts from 44 countries/regions who support Parts I and II.
Pregnancy-Related Heart Disease in the Emergency Department
Hodgson, Nicole R. , Lindor, Rachel A. , Monas, Jessica , Heller, Kimberly, Kishi, Patrick , Thomas, Aaron , Petrie, Cody, Querin, Lauren B. , Urumov, Andrej , Majdalany, David , Majdalany, David S , Urumov, Andrej , Querin, Lauren , Lindor, Rachel A , Heller, Kimberly, Thomas, Aaron, Petrie, Cody

Mayo Clinic

Journal of Personalized Medicine | April 8, 2025 | Volume: 15 | Issue: 4 | Pages: 148

10.3390/jpm15040148 | PMID 40278327 Get It

Pregnancy induces significant physiologic changes that impact the cardiovascular system, potentially exacerbating pre-existing cardiac conditions or precipitating new illnesses. Pregnant patients with cardiac emergencies pose unique challenges, as standard interventions may pose risks to the developing fetus. This article aims to enhance emergency physicians’ confidence in managing pregnancy-related cardiac emergencies by providing a structured approach to initial evaluation and stabilization. We review eight common categories of pregnancy-associated cardiac illness: gestational hypertension and pre-eclampsia, cardiomyopathy, arrhythmias, valvular disease, aortopathies, congenital heart disease and pulmonary hypertension, coronary disease, and anticoagulation-related complications. For each condition, we summarize relevant pregnancy-specific pathophysiology and outline evidence-based, personalized emergency management strategies.